Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm

Dale Han, Daohai Yu, Xiuhua Zhao, Suroosh S. Marzban, Jane L. Messina, Ricardo J. Gonzalez, C. Wayne Cruse, Amod A. Sarnaik, Christopher Puleo, Vernon K. Sondak, Jonathan S. Zager

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background. A consensus for which patients with thin melanomas (B≤ mm) should undergo sentinel lymph node biopsy (SLNB) is not established. We describe a large single institution experience with SLNB for thin melanomas to determine factors predictive of nodal metastases. Methods. Retrospective review from 2005 to 2010 identified 271 patients with thin melanomas who underwent SLNB, along with 13 additional patients not treated with SLNB who developed a nodal recurrence as first site of recurrence. Clinicopathologic characteristics were correlated with nodal status and outcome. Results. Median age was 55 years, and 53 % of patients were male. Median Breslow thickness was 0.85 mm. Overall, a positive sentinel lymph node (SLN) was found in 22 (8.1 %) of 271 cases; 8.4 % of melanomas ≥0.76 mm were SLN positive with 5 % of T1a melanomas ≥0.76 mm and 13 % of T1b melanomas ≥0.76 mm having SLN metastases. Only two of 33 highly selected patients with melanomas<0.76 mm (both T1b) had a positive SLN. Logistic regression analysis demonstrated that mitotic rate ≤1/mm 2 significantly correlated with nodal disease (p<0.05) and ulceration correlated with SLN metastases (p<0.05). Median follow-up was 2.1 years. Overall survival did not differ between positive and negative SLN patients (p = 0.53) but was worse for patients presenting with a nodal recurrence (p<0.01). Conclusions. SLN metastases were seen in 8.4 % of thin melanomas ≥0.76 mm, including 5 % of T1a melanomas ≥0.76 mm. We believe these rates are sufficient to justify consideration of SLNB in these patients, while the indications for SLNB in melanomas<0.76 mm remain to be defined.

Original languageEnglish (US)
Pages (from-to)3335-3342
Number of pages8
JournalAnnals of surgical oncology
Volume19
Issue number11
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Fingerprint

Melanoma
Sentinel Lymph Node Biopsy
Biopsy
Neoplasm Metastasis
Recurrence
cyhalothrin
Sentinel Lymph Node
Logistic Models
Regression Analysis
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Han, D., Yu, D., Zhao, X., Marzban, S. S., Messina, J. L., Gonzalez, R. J., ... Zager, J. S. (2012). Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. Annals of surgical oncology, 19(11), 3335-3342. https://doi.org/10.1245/s10434-012-2469-1

Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. / Han, Dale; Yu, Daohai; Zhao, Xiuhua; Marzban, Suroosh S.; Messina, Jane L.; Gonzalez, Ricardo J.; Cruse, C. Wayne; Sarnaik, Amod A.; Puleo, Christopher; Sondak, Vernon K.; Zager, Jonathan S.

In: Annals of surgical oncology, Vol. 19, No. 11, 01.10.2012, p. 3335-3342.

Research output: Contribution to journalArticle

Han, D, Yu, D, Zhao, X, Marzban, SS, Messina, JL, Gonzalez, RJ, Cruse, CW, Sarnaik, AA, Puleo, C, Sondak, VK & Zager, JS 2012, 'Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm', Annals of surgical oncology, vol. 19, no. 11, pp. 3335-3342. https://doi.org/10.1245/s10434-012-2469-1
Han D, Yu D, Zhao X, Marzban SS, Messina JL, Gonzalez RJ et al. Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. Annals of surgical oncology. 2012 Oct 1;19(11):3335-3342. https://doi.org/10.1245/s10434-012-2469-1
Han, Dale ; Yu, Daohai ; Zhao, Xiuhua ; Marzban, Suroosh S. ; Messina, Jane L. ; Gonzalez, Ricardo J. ; Cruse, C. Wayne ; Sarnaik, Amod A. ; Puleo, Christopher ; Sondak, Vernon K. ; Zager, Jonathan S. / Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. In: Annals of surgical oncology. 2012 ; Vol. 19, No. 11. pp. 3335-3342.
@article{aafa54e0a69e4a48ab1db11706ff1909,
title = "Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm",
abstract = "Background. A consensus for which patients with thin melanomas (B≤ mm) should undergo sentinel lymph node biopsy (SLNB) is not established. We describe a large single institution experience with SLNB for thin melanomas to determine factors predictive of nodal metastases. Methods. Retrospective review from 2005 to 2010 identified 271 patients with thin melanomas who underwent SLNB, along with 13 additional patients not treated with SLNB who developed a nodal recurrence as first site of recurrence. Clinicopathologic characteristics were correlated with nodal status and outcome. Results. Median age was 55 years, and 53 {\%} of patients were male. Median Breslow thickness was 0.85 mm. Overall, a positive sentinel lymph node (SLN) was found in 22 (8.1 {\%}) of 271 cases; 8.4 {\%} of melanomas ≥0.76 mm were SLN positive with 5 {\%} of T1a melanomas ≥0.76 mm and 13 {\%} of T1b melanomas ≥0.76 mm having SLN metastases. Only two of 33 highly selected patients with melanomas<0.76 mm (both T1b) had a positive SLN. Logistic regression analysis demonstrated that mitotic rate ≤1/mm 2 significantly correlated with nodal disease (p<0.05) and ulceration correlated with SLN metastases (p<0.05). Median follow-up was 2.1 years. Overall survival did not differ between positive and negative SLN patients (p = 0.53) but was worse for patients presenting with a nodal recurrence (p<0.01). Conclusions. SLN metastases were seen in 8.4 {\%} of thin melanomas ≥0.76 mm, including 5 {\%} of T1a melanomas ≥0.76 mm. We believe these rates are sufficient to justify consideration of SLNB in these patients, while the indications for SLNB in melanomas<0.76 mm remain to be defined.",
author = "Dale Han and Daohai Yu and Xiuhua Zhao and Marzban, {Suroosh S.} and Messina, {Jane L.} and Gonzalez, {Ricardo J.} and Cruse, {C. Wayne} and Sarnaik, {Amod A.} and Christopher Puleo and Sondak, {Vernon K.} and Zager, {Jonathan S.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1245/s10434-012-2469-1",
language = "English (US)",
volume = "19",
pages = "3335--3342",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm

AU - Han, Dale

AU - Yu, Daohai

AU - Zhao, Xiuhua

AU - Marzban, Suroosh S.

AU - Messina, Jane L.

AU - Gonzalez, Ricardo J.

AU - Cruse, C. Wayne

AU - Sarnaik, Amod A.

AU - Puleo, Christopher

AU - Sondak, Vernon K.

AU - Zager, Jonathan S.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Background. A consensus for which patients with thin melanomas (B≤ mm) should undergo sentinel lymph node biopsy (SLNB) is not established. We describe a large single institution experience with SLNB for thin melanomas to determine factors predictive of nodal metastases. Methods. Retrospective review from 2005 to 2010 identified 271 patients with thin melanomas who underwent SLNB, along with 13 additional patients not treated with SLNB who developed a nodal recurrence as first site of recurrence. Clinicopathologic characteristics were correlated with nodal status and outcome. Results. Median age was 55 years, and 53 % of patients were male. Median Breslow thickness was 0.85 mm. Overall, a positive sentinel lymph node (SLN) was found in 22 (8.1 %) of 271 cases; 8.4 % of melanomas ≥0.76 mm were SLN positive with 5 % of T1a melanomas ≥0.76 mm and 13 % of T1b melanomas ≥0.76 mm having SLN metastases. Only two of 33 highly selected patients with melanomas<0.76 mm (both T1b) had a positive SLN. Logistic regression analysis demonstrated that mitotic rate ≤1/mm 2 significantly correlated with nodal disease (p<0.05) and ulceration correlated with SLN metastases (p<0.05). Median follow-up was 2.1 years. Overall survival did not differ between positive and negative SLN patients (p = 0.53) but was worse for patients presenting with a nodal recurrence (p<0.01). Conclusions. SLN metastases were seen in 8.4 % of thin melanomas ≥0.76 mm, including 5 % of T1a melanomas ≥0.76 mm. We believe these rates are sufficient to justify consideration of SLNB in these patients, while the indications for SLNB in melanomas<0.76 mm remain to be defined.

AB - Background. A consensus for which patients with thin melanomas (B≤ mm) should undergo sentinel lymph node biopsy (SLNB) is not established. We describe a large single institution experience with SLNB for thin melanomas to determine factors predictive of nodal metastases. Methods. Retrospective review from 2005 to 2010 identified 271 patients with thin melanomas who underwent SLNB, along with 13 additional patients not treated with SLNB who developed a nodal recurrence as first site of recurrence. Clinicopathologic characteristics were correlated with nodal status and outcome. Results. Median age was 55 years, and 53 % of patients were male. Median Breslow thickness was 0.85 mm. Overall, a positive sentinel lymph node (SLN) was found in 22 (8.1 %) of 271 cases; 8.4 % of melanomas ≥0.76 mm were SLN positive with 5 % of T1a melanomas ≥0.76 mm and 13 % of T1b melanomas ≥0.76 mm having SLN metastases. Only two of 33 highly selected patients with melanomas<0.76 mm (both T1b) had a positive SLN. Logistic regression analysis demonstrated that mitotic rate ≤1/mm 2 significantly correlated with nodal disease (p<0.05) and ulceration correlated with SLN metastases (p<0.05). Median follow-up was 2.1 years. Overall survival did not differ between positive and negative SLN patients (p = 0.53) but was worse for patients presenting with a nodal recurrence (p<0.01). Conclusions. SLN metastases were seen in 8.4 % of thin melanomas ≥0.76 mm, including 5 % of T1a melanomas ≥0.76 mm. We believe these rates are sufficient to justify consideration of SLNB in these patients, while the indications for SLNB in melanomas<0.76 mm remain to be defined.

UR - http://www.scopus.com/inward/record.url?scp=84868194562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868194562&partnerID=8YFLogxK

U2 - 10.1245/s10434-012-2469-1

DO - 10.1245/s10434-012-2469-1

M3 - Article

C2 - 22766986

AN - SCOPUS:84868194562

VL - 19

SP - 3335

EP - 3342

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 11

ER -